1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
KORU Medical Systems signed Amendment No. 1 to its manufacturing and supply agreement with Command Medical Products on June 24, 2026, covering subassemblies, needle sets and tubing. The amendment extends the initial term to December 31, 2031, makes Command the exclusive manufacturer of a limited set of products, and requires Command to qualify a second manufacturing site by December 31, 2027, with a termination right for KORU if it does not. The filing discloses no financial figures, so its effect on shareholders' results cannot be measured from this document.
Amendment dated June 24, 2026 modifies the January 1, 2024 agreement with Command Medical Products, LLC.
Initial term now expires December 31, 2031, with automatic one-year renewals unless either party gives at least 180 days' notice.
Command must obtain and qualify a second manufacturing site by December 31, 2027; KORU may terminate if Command fails and does not cure within 30 days.
Amendment also changes pricing and payment terms, establishes Command as exclusive manufacturer of a limited set of products, and removes the non-competition provision.
BillionToOne entered a 12-year lease on about 62,659 square feet of office and laboratory space in Union City, California, with base rent of about $46.7 million over the term. The space is meant to add lab capacity for oncology products because test volumes have exceeded the company's plan over the last year, and the company says the facility will expand its total facility space by about 16%. The lease is anticipated to start on or about August 1, 2027.
Lease with Whipple Road Portfolio, LLC signed June 23, 2026, for 3260 Whipple Road, Union City, CA
Aggregate base rent of about $46.7 million over the 12-year term, with a 12-month rent abatement and a tenant improvement allowance of up to $12.5 million
Security deposit of $407,910 payable on signing; lease option to extend 10 years at prevailing market rate
Expected commencement on or about August 1, 2027; full lease text to be filed with the Form 10-Q for the period ended June 30, 2026
Aytu BioPharma and Lannett Company mutually agreed on June 23, 2026 to terminate their exclusive Metadate CD license agreement, except for provisions that survive under a new Termination Agreement. Aytu may keep selling existing inventory at its discretion but must continue royalty reports and payments until those sales cease. The filing reports Metadate CD net revenue of $49,000 for the quarter ended March 31, 2026.
Termination effective June 23, 2026, by mutual agreement with Lannett Company, Inc.
Metadate Agreement dated May 11, 2022, amended July 6, 2023 and July 17, 2025, is terminated in its entirety apart from surviving provisions.
Aytu may sell existing inventory at its sole discretion and must keep providing royalty reports and paying royalties until sales cease.
Metadate CD net revenue was $49,000 for the quarter ended March 31, 2026.
Liberty Energy's subsidiary agreed on June 22, 2026 to buy power generation equipment from Wärtsilä North America for about $332.6 million, for prospective data center and distributed power projects. The filing says delivery and takeover are expected to run from 2029 through 2030, so the spending and project timing extend well beyond the near term.
Contract price is approximately $332.6 million, excluding import taxes, duties, and tariffs, which the purchaser pays where due
Parent company Liberty Energy Inc. is providing a guarantee for payment of the contract price
Delivery, performance testing, and takeover are expected to begin in 2029 and continue through 2030
Either party may terminate for material breach or continuing force majeure, subject to refunds or damages; full contract to be filed with the 10-Q for the quarter ending June 30, 2026
Galectin Therapeutics said its Type C meeting with the FDA produced agreement on the primary endpoint and regulatory path for a potential full approval of belapectin in patients with MASH cirrhosis and portal hypertension. The company plans to file the Phase 3 protocol in the third quarter of 2026 and is exploring strategic and financial partnerships to support development.
FDA agreed to a composite liver outcome primary endpoint that includes prevention of large esophageal varices (>5 mm)
FDA accepted the company's proposed blinded central review process for endoscopic assessments, based on the NAVIGATE trial approach
Company plans a single 2 mg dose in the Phase 3 trial and expects a trial size generally comparable to NAVIGATE
Phase 3 protocol submission anticipated in the third quarter of 2026; company is actively pursuing partners
AnaptysBio entered a 12-month sublease on June 15, 2026, leasing about 45,057 rentable square feet of its San Diego premises to First Tracks Biotherapeutics. The company stays responsible for its underlying master lease, and the sublease ends if its own tenancy ends, so the deal shifts occupancy costs to a subtenant without changing the company's core obligations.
Sublease covers about 45,057 rentable square feet at 10770 Wateridge Circle, San Diego, under a master lease with Wateridge Property Owner, LP.
First Tracks pays monthly rent equal to the Basic Rent and Additional Rent AnaptysBio owes under the master lease, due in advance on the first of each month.
Initial term is 12 months from June 15, 2026; First Tracks has a renewal option capped at April 4, 2028 and may terminate on three months' notice.
LifeMD entered into agreements with Antares Pharma, a subsidiary of Halozyme, to co-market a direct-to-patient self-pay program for XYOSTED, a testosterone injection. LifeMD will be the exclusive telehealth co-marketing partner, and its pharmacy will be the preferred dispensing pharmacy. The filing does not disclose financial terms or dollar amounts for the deal, so its near-term effect on LifeMD's results cannot be measured from this filing.
The program launches in July 2026 and will initially be available in 37 states.
The company's all-inclusive program price is approximately $249 per month, covering medication and care, per the attached press release.
The agreements have an initial three-year term with automatic one-year renewals unless either party gives 90 days' written notice.
Either party may terminate the Statement of Work if budgeted marketing investments are missed for two consecutive quarters.
Fluent, Inc. announced the launch of Fluent In-Store, a commerce media offering that extends its advertising solutions to physical retail locations by activating on point-of-sale devices after payment. The offering is built on a partnership with Bilt Technologies, Inc., and the initial proof-of-concept at Beyond, Inc. retail locations is targeted to launch between mid-July and August 2026, with no financial results or financial terms disclosed.
Fluent In-Store activates on point-of-sale devices after payment completion to deliver identity-resolved offers with full-funnel measurement.
Offering is built on a partnership with Bilt Technologies, Inc., a rewards and payments network.
Initial proof-of-concept at Beyond, Inc. retail locations is targeted to launch mid-July to August 2026.
Ambow Education Holding Ltd. announced on June 18, 2026 the launch of HybriU ProjectHub, a project collaboration and knowledge platform within its HybriU platform. The filing furnishes the press release as an exhibit and contains no financial results, guidance, or deal terms.
Product available immediately from June 18, 2026 at projecthub.hybriu.com
Features include an AI assistant that generates summaries and reports, role-based access control, and live collaboration sessions
Second HybriU product launch in 2026, following the HybriU Collaboration Board
In a shareholder letter issued June 17, 2026, CEO Peter Holst said TaoWeave is moving from holding TAO tokens in the Bittensor ecosystem to building an operating business on top of it. The company invested $1 million in Manako Labs Ltd. in May 2026 and became its commercialization partner for the United States and Canada, but the letter says the platform is in early deployment and meaningful revenue is expected to take quarters to materialize.
Invested $1 million in Manako Labs Ltd. in May 2026 and secured a multi-year role as its US and Canada commercialization partner
Platform remains in early deployment, with testing at initial customer sites rather than broad commercial availability
Company evaluated approximately 30 teams building on Bittensor over roughly eight months before choosing this application
First substantive progress update is expected with second-quarter results in August 2026
OraSure Technologies said the FDA cleared its Colli-Pee Dx Urine Collection Kit, made by subsidiary DNA Genotek, for use with Roche Molecular Systems tests for four sexually transmitted infections run on Roche's cobas 5800, 6800 and 8800 systems. The kit supports at-home self-collection of first-void urine for male and female patients. The filing does not provide financial figures or a sales outlook tied to the clearance.
FDA clearance announced June 11, 2026, for the Colli-Pee Dx Urine Collection Kit from DNA Genotek Inc.
Cleared for use with Roche tests for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis and Mycoplasma genitalium
Compatible with Roche cobas 5800, 6800 and 8800 molecular diagnostic systems
Kit supports at-home self-collection of first-void urine for male and female patients
Abundia Global Impact Group said it entered a long-term agreement with Frankfort Plastics to supply 40,000 tons per year of polyolefin plastic waste to its Cedar Port Waste to Fuels facility. The company says the volume is about 50% of the expected feedstock requirement for its first planned Cedar Port plant, but the filing does not disclose any financial terms or dollar value.
Frankfort Plastics committed to supply 40,000 tons per year for ten years, with an option for Abundia to buy additional volumes
The volume represents approximately 50% of the expected feedstock requirement for the first planned Cedar Port plant
Commercial terms are binding, with definitive agreements expected to be executed in 3Q 2026
The forward-looking statements cite liquidity needs, the need for additional financing, and going concern risk
Falcon's Beyond Global said its subsidiary Falcon's Attractions entered a Master Consulting Services Agreement with VAI Amusement Park, LLC on June 2, 2026. The subsidiary will act as lead design consultant for a theme park to be built in Arizona, under an agreement valued at about $10.6 million. The filing describes a routine service contract of modest size relative to the deal's stated value, with payments tied to project milestones.
Agreement signed June 2, 2026 with VAI Amusement Park, LLC
Falcon's Attractions to provide master plan design and related consulting as lead design consultant
Agreement valued at approximately $10,600,000, with milestone-based payments over project execution periods
TaoWeave, Inc. disclosed an investment of $1 million in Manako Labs Ltd., a Physical AI company, along with a technology license and distribution agreement giving it North American commercialization rights and a share of licensing revenue. The filing also describes a Simple Agreement for Future Equity, a lock-up agreement, and warrants issued under a private placement exemption, but it does not state expected revenue or the size of the equity stake.
TaoWeave invested $1 million in Manako Labs Ltd. and will earn revenue from licensing agreements, according to the June 1, 2026 press release.
Agreements with Manako Labs are dated May 28, 2026 (license and SAFE) and May 29, 2026 (lock-up).
Warrants were issued under the Section 4(a)(2) exemption and Regulation D, without a public offering.
The filing gives no revenue projections or financial results for the transaction.
HCI Group and its insurance subsidiaries and sponsored reciprocal insurers placed three reinsurance towers covering June 1, 2026 through May 31, 2027 to mitigate catastrophe risk such as hurricanes. HCI expects net reinsurance premiums ceded to third parties, excluding its reinsurance subsidiaries, of about $381.2 million for the period, an estimate subject to a true-up on September 30, 2026.
Reinsurance Tower 1 provides up to $1.06 billion for a single Florida event and $1.96 billion total coverage, with a $10.0 million retention.
Tower 2 provides up to $830.3 million for a single Florida event and $605.0 million for a single event outside Florida, with $1.45 billion total coverage.
Tower 3 provides up to $431.5 million for a single Florida event and $649.7 million total coverage, with a $2.8 million retention.
Claddaugh and Fortex Re maximum estimated retained loss is about $139.8 million for the first event and $52.3 million for the second event.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.